Minims Tropicamide Bausch + Lomb Ireland Limited (Tropicamide)

Tropicamide works by selectively blocking muscarinic (M3) receptors on the iris sphincter and ciliary body. This inhibition prevents acetylcholine‑mediated contraction, causing the iris sphincter to relax and the pupil to enlarge, while also reducing the eye’s ability to accommodate, resulting in cycloplegia.

The specific dosing regimen is determined by the prescribing clinician based on the intended examination or procedure. Typically, one to two drops are instilled in the conjunctival sac of the affected eye(s), but the exact number of drops, frequency, and timing are set by the eye care professional.

The pregnancy category for tropicamide is listed as unknown. It should only be used during pregnancy or lactation when the potential benefit justifies any possible risk to the fetus or infant, and after consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Minims Tropicamide. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature controls), and necessary import documentation.

Tropicamide provides rapid onset and relatively short duration of dilation compared with agents like phenylephrine, which primarily stimulates the dilator muscle, or cyclopentolate, which has a longer cycloplegic effect. Tropicamide’s antimuscarinic action offers reliable mydriasis with a favorable safety profile for routine diagnostic use.

Store the eye‑drop bottles at room temperature, preferably below 25 °C. Keep them in the original packaging, protect from direct light, and ensure the cap is tightly closed to maintain sterility. Do not freeze the product.

The solution is applied topically to the eye. After washing hands, tilt the head back, gently pull down the lower eyelid to form a pocket, and place the prescribed number of drops into the conjunctival sac. Close the eye briefly to allow distribution, then avoid blinking excessively for a few seconds.

The most serious adverse events include acute angle‑closure glaucoma, which can cause severe eye pain and vision loss, and systemic anticholinergic toxicity, though rare, presenting with symptoms such as dry mouth, tachycardia, or confusion. Prompt medical attention is required if these occur.

Patients with known hypersensitivity to tropicamide or any component of the formulation should avoid it. Individuals with narrow‑angle or uncontrolled glaucoma, severe ocular inflammation, or those who have recently used miotic agents should not receive tropicamide without specialist assessment.